Section Arrow
XBIO.NASDAQ
- Xenetic Biosciences
Quotes are at least 15-min delayed:2024/06/18 07:47 EDT
Last
 4.1099
+0.2501 (+6.48%)
Day High 
4.15 
Prev. Close
3.8598 
1-M High
4.15 
Volume 
11.98K 
Bid
3.71
Ask
4.18
Day Low
3.79 
Open
3.79 
1-M Low
3.51 
Market Cap 
5.95M 
Currency USD 
P/E -- 
%Yield
10-SMA 3.92 
20-SMA 3.84 
50-SMA 4.02 
52-W High 5.97 
52-W Low 2.8696 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.93/-0.73
Enterprise Value
6.16M
Balance Sheet
Book Value Per Share
5.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.54M
Operating Revenue Per Share
1.40
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.4288-0.0209-4.65%-- 
MBIOMustang Bio0.75+0.62+476.92%-- 
NLSPNLS Pharmaceutics Ltd0.1483+0.034378+30.18%-- 
SCNIScinai Immunotherapeutics Ltd.5.6+2.11+60.46%-- 
AZTRAzitra0.2337+0.0844+56.53%-- 
Quotes are at least 15-min delayed:2024/06/18 07:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.